HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

Impact · against what's priced in

The Phase III SAFFRON data provides a material positive catalyst for AstraZeneca by expanding Tagrisso's utility in MET-driven EGFR-mutated lung cancer. The significant reduction in disease progression and death risks supports a likely regulatory filing and subsequent revenue growth.

AZN+0.80: No priced-in read yet

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

What matters in this story

How each ticker is affected

Roche says divarasib cut risk of death 44% in lung cancer trial

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

What matters in this story

How each ticker is affected

Roche says divarasib cut risk of death 44% in lung cancer trial

Track these names every morning.

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

AstraZeneca Readies New Portfolio of Targeted Cancer Therapies

Roche Targets Emerging Oncology Market With New Lung-Cancer Drug

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

What matters in this story

How each ticker is affected

Next reads from the same story arc

Roche says divarasib cut risk of death 44% in lung cancer trial

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

What matters in this story

How each ticker is affected

Next reads from the same story arc

Roche says divarasib cut risk of death 44% in lung cancer trial

Track these names every morning.

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

AstraZeneca Readies New Portfolio of Targeted Cancer Therapies

Roche Targets Emerging Oncology Market With New Lung-Cancer Drug

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026